Oct 1 (Reuters) – AbbVie Inc.: * ABBVIE – PHASE 3 STUDIES SHOW CONTINUED REPIGMENTATION WITH RINVOQ THROUGH WEEK 76 * ABBVIE – RINVOQ PLUS NB-UVB SHOWS HIGHER REPIGMENTATION THAN RINVOQ ALONE
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
By Saeed Azhar NEW YORK, Nov 16 (Reuters) - Nvidia's $500 billion AI financing platform…
By Anhata Rooprai and Vidya Ranganathan BENGALURU/LONDON, Nov 16 (Reuters) - The sudden departure of…
Nov 16 (Reuters) - Berkshire Hathaway Inc: * BERKSHIRE HATHAWAY: WARREN E. BUFFETT, CHAIRMAN EMERITUS,…
Nov 16 (Reuters) - Prysmian CEO Massimo Battaini says at an event in Milan: *…
VIDEO SHOWS: ARCHIVE FOOTAGE OF BELGIUM'S ROMELU LUKAKU SHOWS: TUBIZE, BELGIUM (ARCHIVE - NOVEMBER 14,…
By Anhata Rooprai and Vidya Ranganathan BENGALURU/LONDON, Nov 16 (Reuters) - The sudden departure of…